Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

AlphaFold-driven structural proteomics reveals extensive cellulosome machinery in human ruminococcal symbionts

Minor C, Takayesu A, Arbing MA, Ha SM, Gunsalus RP, Pellegrini M, Sawaya MR, Clubb RT. AlphaFold-driven structural proteomics reveals extensive cellulosome machinery in human[...]

Unraveling the autoimmune architecture of pemphigus: from B-cell depletion to network-based immune engineering

Shafiei-Jahani P, Li X, Akbari A, Vera A, Haniff E, Carlisle R, Akbari O, Holland V. Unraveling the autoimmune architecture of pemphigus: from B-cell depletion[...]

Cerebriform Ridges on the Scalp Signaling a Tumor in the Brain

Park A, Kenney S, Kellogg C, Castillo JR, Bergheim T. Cerebriform Ridges on the Scalp Signaling a Tumor in the Brain. Perm J. 2026 Jul[...]